Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
Objective: To investigate the impact of non-motor fluctuations for QOL in patients with Parkinson's disease (PwPD) using a nine-item wearing-off questionnaire (WOQ-9). Background: Long-term levodopa…Autosomal recessive Primary Familial Brain Calcification caused by MYORG mutations. Two unrelated cases from the south of Chile
Objective: To describe two unrelated cases of AR- PFBC with mutations in MYORG gene. Background: Primary Familial Brain Calcification (PFBC) is a rare neurogenetic disorder…Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic
Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…Quantification motor improvement from levodopa carbidopa infusion gel therapy in patients with Parkinson’s disease using a wearable device.
Objective: To evaluate the feasibility of using a wearable device to objectively quantify the motor improvement of a Parkinson Disease patient with a therapy modification…Effectiveness of non-invasive therapy of tPCS & peripheral nerve stimulation on Ataxia patients
Objective: A pilot study to determine the effectiveness of a combination of transcranial pulsed current stimulation and pulsed current peripheral nerve stimulation as a novel…Cost-effectiveness of Lee Silverman Voice Treatment LOUD (LSVT®) versus NHS Speech and Language Therapy versus control for dysarthria in Parkinson’s disease: An economic evaluation alongside the PD COMM trial
Objective: We evaluated the cost effectiveness of two speech and language therapy techniques compared with no therapy in people with Parkinson's disease who have problems…The prevalence of delirium and subsequent outcomes in inpatients with Parkinson’s disease
Objective: To report delirium prevalence in hospitalised Parkinson’s disease (PD) participants compared to older adults and examine the association with mortality in a prospective study.…Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease
Objective: To investigate functional alterations of the p.V15A variant in alpha-Synuclein (α-Syn) in Parkinson's disease (PD). Background: PD is marked by the loss of dopaminergic…Discriminative properties and sensitivity to change of three cognitive assessment instruments in Huntington’s disease
Objective: We addressed and compared the discriminative properties of different cognitive instruments, and we determined the sensitivity to change of the proposed assessments in the…SYNCHRONIZE: Real-world retrospective safety analysis in patients treated with onabotulinumtoxinA for more than one therapeutic indication
Objective: Report real-world safety of onabotulinumtoxinA used concomitantly for multiple therapeutic indications. Background: Therapeutic onabotulinumtoxinA is approved in the US for 12 indications, some of…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 186
- Next Page »